Hyundai Motor will launch the Genesis brand in Europe this summer, initially, the G80 sedan and the GV80 SUV, to gain a share in the high-end and electric vehicle markets.
The South Korean carmaker will also introduce the G70 sedan, the GV70 SUV, and a strategic model customized for European markets this year.
In its broad expansion strategy, Hyundai will place the G80 electrified and two other all-electric models under the Genesis brand in Europe by 2022.
The Genesis lineup consists of the G70, G80, and G90 sedans, and the GV70 and GV80 SUVs.
Hyundai will launch the G80 and the GV80 in China this year, hoping to revive sluggish sales in the market.
After launching the Genesis brand domestically in 2015, Hyundai has released Genesis models in the US, Canada, Australia, Russia, the Middle East.
Last month, Hyundai unveiled the Genesis X electric concept as it aims to eventually fill the lineup with zero-emission models in line with market trends.


SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Silver Prices Plunge in Asian Trade as Dollar Strength Triggers Fresh Precious Metals Sell-Off
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Washington Post Publisher Will Lewis Steps Down After Layoffs
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices
RBI Holds Repo Rate at 5.25% as India’s Growth Outlook Strengthens After U.S. Trade Deal
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 



